Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06025500

Analysing Peripheral Skeletal Muscle Function Before and After Endobronchial Valve Treatment

Rationale: Chronic obstructive pulmonary disease (COPD) is characterised by a high prevalence of peripheral muscle dysfunction, which can have significant clinical consequences, including decreased exercise capacity, reduced quality of life, and even a higher mortality rate. Reduction of lung hyperinflation using bronchoscopic lung volume reduction treatment with one-way endobronchial valves (EBV) is a minimally invasive intervention which improves exercise capacity and physical activity in patients with severe emphysema. This positive effect is also related to weight gain and alterations in body composition. The physiologic and structural adaptations of skeletal muscle function after EBV treatment has never been investigated before.

Objective: To investigate the physiological and structural adaptations of peripheral muscle function at a cellular level in response to EBV treatment.

Study design: A single center, prospective clinical trial with a single-arm pretest-posttest design. Patients with severe emphysema who will receive a bronchoscopic lung volume reduction treatment are asked to undergo additional in-magnet exercise testing and muscle biopsies before and after placement of EBVs.

Study population: Patients with severe emphysema who are scheduled to undergo EBV treatment.

Main study parameters/endpoints: The difference in quadriceps phosphocreatine concentration (PCr), quadriceps inorganic phosphorus concentration (Pi), and quadriceps pH at rest, during progressive exercise, and recovery rate will be measured by 31P-MRS to assess the physiological effect of EBV treatment on skeletal muscle function and its bioenergetics. Furthermore, we will perform a detailed histological and biochemical analysis of muscle fiber type composition, mitochondrial density, master regulators of muscle oxidative programming, and mitochondrial respiration before and after EBV treatment.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Univeristy Medical Center Groningen

Groningen, Netherlands

Location status: Recruiting

Location contact

Else ter Haar, MD

CONTACT

Jorine Hartman, PhD

CONTACT

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is scheduled for a bronchoscopic lung volume treatment using one-way endobronchial valves;
  • Patient read, understood and signed the Informed Consent Form.

Exclusion criteria

  • Inability to perform a cycle ergometry test;
  • Contraindications for undergoing a magnetic resonance imaging scan (e.g. claustrophobia, implanted cardiac devices);
  • Body length >190cm;
  • Any anticoagulant therapy;
  • COPD exacerbation 4 weeks prior to testing.

Treatment and study plan

31P-Magnetic Resonance Spectroscopy (31P-MRS)

Diagnostic Test

31P-Magnetic Resonance Spectroscopy will be performed during exercise testing.

Other names: Muscle biopsy

Primary outcomes

  1. Change in quadriceps phosphocreatine concentration measured by 31P-MRS.

    Time frame: 6 months

    To assess the physiological adaptations, in terms of cellular bioenergetics, of the quadriceps muscle in patients with severe COPD in response to EBV treatment. This will be done by performing 31P-MRS during exercise testing in a MR-compatible ergometer at baseline and at 6 months follow-up, for which the quadriceps phosphocreatine concentration (PCr) at rest and during progressive exercise will be assessed.

Secondary outcomes

  1. Change in muscle fiber type composition measured in muscle biopsies.

    Time frame: 6 months

    Change in muscle fiber type composition 6 months after EBV treatment measured in muscle biopsies.

Study contacts

Contact information is provided by the study sponsor or research team.

Else ter Haar, MD

CONTACT

[email protected]

+31503619194

Jorine Hartman, PhD

CONTACT

[email protected]

+31503619194

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Registry information

Official study title

Analysing cEllular Bioenergetics aNd Structural aDaptations in the qUadriceps Muscle befoRe and After endobroNChial Valve treatmEnt

Acronym: ENDURANCE

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 6, 2023
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.